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Abstract Congenital disorders of glycosylation are a
growing group of inborn errors of protein glycosylation.
Cardiac involvement is frequently observed in the most
common form, PMM2-CDG, especially hypertrophic car-
diomyopathy. Dilated cardiomyopathy, however, has been
only observed in a few CDG subtypes, usually with a lethal
outcome. We report on cardiac pathology in nine patients
from three unrelated Israeli families, diagnosed with
dolichol kinase deficiency, due to novel, homozygous
DK1 gene mutations. The cardiac symptoms varied from
discrete, mild dilation to overt heart failure with death.
Two children died unexpectedly with acute symptoms of
heart failure before the diagnosis of DK1-CDG and heart
transplantation could take place. Three other affected
children with mild dilated cardiomyopathy at the time of
the diagnosis deteriorated rapidly, two of them within days
after an acute infection. They all went through successful
heart transplantation; one died unexpectedly and 2 others
are currently (after 1–5 years) clinically stable. The other 4
children diagnosed with mild dilated cardiomyopathy are
doing well on supportive heart failure therapy. In most
cases, the cardiac findings dominated the clinical picture,
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without central nervous system or multisystem involve-
ment, which is unique in CDG syndrome. We suggest to
test for DK1-CDG in patients with dilated cardiomyopathy.
Patients with discrete cardiomyopathy may remain stable
on supportive treatment while others deteriorate rapidly.
Our paper is the first comprehensive study on the pheno-
type of DK1-CDG and the first successful organ trans-
plantation in CDG syndrome.
Keywords Dilated cardiomyopathy  Heart failure 
CDG-Im  Congenital disorders of glycosylation 
Dolichol kinase deficiency  Cardiac transplantation
Introduction
The process of N-linked protein glycosylation comprises a
pathway from the cytoplasm to the endoplasmic reticulum
(ER) and the Golgi compartment [1–3]. A recent classifi-
cation of CDGs distinguishes four major biochemical cat-
egories: three involving protein glycosylation (disorders of
N-linked glycosylation, O-linked glycosylation, and com-
bined N- and O-glycosylation) and one involving lipid
glycosylation [2]. Plasma transferrin isoelectric focusing
(TIEF) is used as a simple and reliable biochemical
screening tool for CDG [4]. Depending on the localization
of a defect, two isofocusing patterns can be distinguished.
The so-called type 1 pattern demonstrates increases in even
di- and asialotransferrin bands (previously CDG-I). The
type 2 pattern shows additional uneven tri- and monosi-
alotransferrin bands (previously CDG-II) [4]. CDG is
generally associated with multi-organ symptoms, including
psychomotor retardation, ataxia, polyneuropathy, epilepsy,
endocrine abnormalities, growth retardation, visual and
hearing loss, ichthyosis, cardiac, renal, liver, and gastro-
intestinal involvement [2, 5–9]. The patients with this
syndrome may show a wide clinical variability; however,
both hypertrophic [3, 10–15] and/or dilated cardiomyopa-
thy [16–19] have been described.
Dilated cardiomyopathy has been long known to be
associated with various inborn errors of metabolism. In
many cases, DCM has been associated with abnormal
mitochondrial function, like in Kearns-Sayre syndrome
(MIM 530000), Acyl-CoA dehydrogenase family member
9 deficiency (MIM 611126), ATP-ase deficiency (MIM
604273), or Barth syndrome (MIM 302060) [20], and also
with diverse defects of fatty acid oxidation (Carnitine
palmitoyl transferase defect type II; MIM 600649, Long
chain Acyl-CoA dehydrogenase defect; MIM 201475,
Carnitine deficiency; MIM 212140) or storage disorders
(like GM1 gangliosidosis; MIM 230500, haemochromato-
sis; MIM235200).
Normal glycosylation might also be important for car-
diac function. DCM is one of the most important clinical
features in DPM3-CDG (MIM 612937) and is observed in
tissue-specific types of O-linked mannosylation (Muscular
dystrophy-dystroglycanopathy; MIM 607155) [17, 19]. The
first description of dilated cardiomyopathy in ALG6-CDG
was recently reported in a 9-year-old boy [18]. The child
was subsequently placed on ACE inhibitors, and 5 years
later, he was weaned off with stabilization of the cardiac
function. A lethal form of DCM has been described in
DK1-CDG (dolichol kinase defect, MIM 610768; 9q34.11
due to mutations in TMEM15, also labeled as the DK1 and
DOLK gene) [2, 17].
DCM is often diagnosed due to signs and symptoms
of advanced heart failure, where cardiac dilatation and
impaired contractility are recognized, often in the absence
of a recognized etiology. However, initial clinical presen-
tation may be with severe complications: thromboembo-
lism, arrhythmia, or sudden death [21]. Beyond infancy,
cardiomyopathy is the most important indication for heart
transplantation during childhood. In this work, we report on
the cardiac phenotype at presentation and during follow-up
of nine DK1-CDG pediatric patients from 3 unrelated
families.
Patients and methods
The diagnosis of dilated cardiomyopathy was made using
the standard American and European guidelines for LV
size and systolic function in children. In line with these
recommendations for standardizing measurements from
M-mode echocardiography, it is possible to judge echo-
cardiographic measurements of a particular patient as
normal or abnormal using the Z-scores (http://www.para
meterz.com, calculate BSA-adjusted Z-scores for common
M-Mode measurements; LV end-diastolic and -systolic
dimensions, LVEDD and LVESD, respectively). The
standard M-mode method of LV systolic function assess-
ment is the shortening fraction (SF). In patients at high risk
for diminished function (e.g., SF less than 28%), serial
assessments were done. The criteria for the severity of the
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disease include not only echocardiographic data but also
symptoms and function. Mild dilated cardiomyopathy was
defined as LV-Z score diameters just above ?2SD. Severe
dilated cardiomyopathy combined both Z-scores much
higher than ?2SD with diminished LV (and RV) systolic
function, often accompanied by symptoms.
The clinical phenotype of all patients is described in
Table 1.
Family I
Patient I/2, the second male child of healthy, consanguineous
parents of Druze origin (Fig. 1) was clinically healthy till the
age of 9 years when he was acutely admitted with fulminate
heart failure due to dilated cardiomyopathy of unknown eti-
ology (LVEDD and LVESD Z-scores unknown). Patient I/5,
sister of patient I/2, was asymptomatic when diagnosed with a
dilated cardiomyopathy at age 7 (LVEDD and LVESD
Z-scores 2.18 and 2.58, respectively). Patient I/6, a younger
sister of patient I/5, had a history of mild hypotonia, failure to
thrive, short stature, and ichthyosiform dermatitis. She was
diagnosed with mild dilated cardiomyopathy (LVEDD and
LVESD Z-scores 2.27 and 2.38, respectively) at the age of 6
without any clinical symptoms.
Family II
Patient II/2, the second male child of healthy, consan-
guineous parents of Druze origin (and not related to the
former Druze family, Fig. 1) was diagnosed with failure to
thrive and elevated transaminases during infancy. At
6 years of age, a mild asymptomatic dilatation of the left
ventricle was detected on echocardiogram (LVEDD and
LVESD Z-scores 2.27 and 2.29, respectively). Patient II/3,
the younger brother of patient II/2, was clinically asymp-
tomatic and was known with mild hypertransaminasemia.
At the age of 5 years, his echocardiography revealed mild
dilated cardiomyopathy (LVEDD- and LVESD Z-scores of
2.27 and 2.81, respectively).
Family III
Patient III/2, the second male child of healthy, consan-
guineous parents of Beduin origin (see also Fig. 1) was
known with recurrent episodes of severe neutropenia,
microcytic anemia, and frequent infections. At the age of
9 years, he was referred for heart transplantation due to
severe heart failure (Class IV modified Ross Heart Failure
Classification for Children, LVEDD- and LVESD Z-scores
at presentation 3.57 and 7.29, respectively), with repeated
life-threatening episodes of rhythm disturbances (e.g.,
ventricular fibrillation). Patient III/1, his older sister,
and Patients III/3 and III/4, two younger brothers, were
asymptomatic and showed mild to moderate dilated car-
diomyopathy on repeated echocardiograms (LVEDD- and
LVESD Z-scores at presentation: patient III/1 2.06 and
2.29, respectively; patient III/3 2.64 and 2.43, respectively;
patient III/4 2.5 and 1.93, respectively).
Laboratory investigations
Studies were carried out in all patients alive at the time of the
diagnosis of CDG. These included blood cell count, hemo-
globin, creatine kinase, liver enzymes, electrolytes, kidney
function, prothrombin, activated partial thromboplastin
time, cholesterol, triglycerides, thyroid-stimulating hor-
mone, free T4, and albumin level measurements. Additional
coagulation studies were performed in most patients (anti-
thrombin 3, factor IX and XI, protein C and S activity).
Genetic investigations
Based on homozygosity data obtained during routine 250 k
SNP array analysis performed in Family I and Family II,
and using the results of the biochemical investigations,
we selected DK1 as a candidate gene in our patients.
Sequencing of all exons of DK1 (TMEM15 or DOLK) [17]
was performed using the ABI PRISM BigDye Terminator
Cycle Sequencing V2.0 Ready Reaction Kit and analyzed
with the ABI PRISM 3730 DNA analyzer (Applied Bio-
systems, Foster City, USA) (see Table 2).
Metabolic studies
Plasma samples were collected from EDTA or heparin
blood by centrifugation and stored at –20C. Isoelectric
focusing (IEF) of serum transferrin was performed as
described [22]. In Patient II/2, impaired glycosylation
(CDG-Ix) was diagnosed at the age of 4 years [16].
Three children had repeated TIEF analysis upon cardiac
transplantation.
Enzyme activity of dolichol kinase was assessed in
patient fibroblasts by incubation of C19-dolichol with
g32P-CTP. DOLK1 deficiency was confirmed in the
fibroblast lines of the index patients from all 3 families.
Pathological examination
Light microscopy was performed after cardiac tissue was
embedded in paraffin. Serial sections of the tissue were
evaluated and stained by hematoxylin and eosin, Masson
trichrome, Congo red, and phosphotungstic acid hematox-
ylin. Electronmicroscopic examination was performed in
one patient following standard protocols. Thick sections
were made of each tissue block and stained with toluidine
blue.
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Results
Family I
Patient I/2 died after an unsuccessful resuscitation for non-
sustained ventricular tachycardia without finding the
underlying etiology.
Patient I/5 developed a slowly progressive cardiac dis-
ease. She was treated with oral Carnitine, diuretics, and
Digoxin, and later on with Angiotensin Converting
Enzyme (ACE) inhibitors and b blockers with no
improvement of the cardiac function. Five years later,
while waiting for cardiac transplantation for at least 1 year,
she exhibited frequent multifocal premature ventricular
beats, and later also non-sustained ventricular tachycardia
that was treated with Amiodarone. The girl deteriorated
rapidly into class IV modified Ross Heart Failure Classi-
fication for Children and needed high inotropic cardiac
support (e.g., Dobutamine i.v.). Shortly after, at the age of
12, she received heart transplantation and almost 6 years
later, she is doing well without episodes of rejection and
allograft coronary artery disease.
Patient I/6 was treated with oral supportive therapy of
diuretics, Digoxin, ACE inhibitors and b blockers. At age
10, a transient decrease in the cardiac function was
observed during viral infection with a short period of
diarrhea, severe neutropenia, and thrombocytopenia (the
latter resolved after 10 days). Bone marrow aspiration was
normal. At the age of 15 years, following an infection with
Fig. 1 Pedigree of three families with DK1-CDG
Table 2 Laboratory values in 9 patients with DK1-CDG
Patients I/2 I/5 I/6 II/2 II/3 III/1 III/2 III/3 III/4
Microcytic anemia NA ? ? ± ? ? ? ? ?
Decreased serum iron levels NA – – ? – ? NA ? –
Leucopenia NA ? ? ? – ? NA ? ?
Neutropenia/lymphocytosis NA – – ? ? ? ? ? ?
Thrombopenia NA – – – – – NA –
Elevated liver transaminases NA ? ? ? ? – NA – –
Elevated creatine kinase NA – – – – – NA – –
Abnormal coagulation studies:
Decreased Factor IX activity NA – – – – – NA – –
Decreased Factor XI activity NA – ?(12%)$ ?(32%) ?(26%) ? 34%) NA ?(17%) ?(28%)
Decreased AT-III activity NA ? ? ? ? ? NA
Decreased protein C activity NA ? ?(26%)$ ?(43%) ?(17%) ?(48%) NA ?(37%) ?(32%)
Prolonged PT NA ? ? ? ? ? NA ? ?
Prolonged APTT? NA – ? – ? – NA ? ?
Abnormal endocrine studies
Cortisol/ACTH NA NA Normal Low/NA Normal Low NA Normal Normal
Growth hormone/IGF1 NA NA Normal Normal Normal Normal NA Normal Normal
Insulin NA NA NA NA NA NA NA NA NA
Thyroid function NA Normal Normal Normal Normal Normal NA Normal Normal
Genetic investigations
Hom. c.1222C [ G; (p.His408Asp) Hom. c.1222C [ G; (p.His408Asp) Hom. c.912G [ T; (Trp304Cys)
Type I transferrin pattern ? ? ? ? ? ? ? ? ?
NA data not available (not assessed), TIEF transferrin isoelectric focusing
1 Activated partial thromboplastin time
$ After the transplantation
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influenza H1N1, she presented with tachypnoa, diaphoresis
at rest, extreme fatigue (class IV modified Ross Heart
Failure Classification), and non-sustained ventricular
tachycardia treated with Amidarone. Due to rapid deteri-
oration, she was put on ECMO as bridging treatment for
successful heart transplantation 6 days later.
Two months later, she presented with rhythm disturbances
during viral infection and was treated successfully with Ami-
odarone and pulse therapy with high dose steroids (Solomedrol
i.v.) due to a suspected episode of humoral rejection.
During the first one and a half year after the heart
transplantation, she was doing well except for repeated
herpetic infections, low weight gain, short stature, and
delayed puberty. She then died unexpectedly at home.
Permission for autopsy was not given.
Family II
Patient II/2 was diagnosed with asymptomatic cardiac
dilatation and was treated with low doses ACE inhibitors
for 4 years. At age of 11.5, after a short period of upper
respiratory tract infection, the boy presented with acute
abdominal pain, vomiting, ascites, and peripheral edema.
Clinical examination, ECG, and repeated echocardiogra-
phy demonstrated acute cardiac failure with severe biven-
tricular dilatation of the heart that did not improve with
adequate intravenous diuretics, ACE blockers, and high
doses inotropics (e.g., Dobutamin and later also Levosi-
medan i.v.). Few weeks later, he went through heart
transplantation.
The post-transplantation pericardial effusion resolved
within a few weeks. Twelve months later, he is doing well
on maintenance therapy (immunosuppressive medication,
low dose steroids, and diuretics). The child is visiting
school on regular basis and is playing football (class I
modified Ross Heart Failure Classification).
Patient II/3, in spite of being asymptomatic with only
mild cardiac dilatation, was treated with low doses ACE
inhibitors from the age of 5 years. After his brother
underwent heart transplantation, b blockers and diuretics
were added to his medications in order to try to avoid
further cardiac deterioration.
Five years later on supportive therapy, he is still
asymptomatic. His ECG demonstrates normal sinus
rhythm, with bifascicular block (incomplete right bundle
branch block and left anterior hemi-block), slow upcoming
T wave, and QTc of 0.45 s (see Fig. 2a). The ECG was
almost identical to the pre-transplantation ECG of his older
brother (see Fig. 2b); the latter showing also increased
atrial forces (tall p wave). On echocardiography, no further
dilatation of his LV diameters has been seen (LV end-
diastolic and end-systolic diameters of 44.5 and 30 mm,
z-scores of 2.43 and 2.29, respectively).
Family III
Patient III/2 presented with high fever, cough, vomiting,
peripheral edema and extreme tachypnea, and fatigue
(Class IV modified Ross Heart Failure Classification).
Upon repeated life-threatening episodes of ventricular
fibrillation, he was referred for heart transplantation. He
died after unsuccessful resuscitation within 1 month from
the first presentation, before a donor heart was available.
Patient III/1, his older sister, and Patients III/3 and III/4,
two younger brothers, showed asymptomatic (Class I),
mild to moderate dilated cardiomyopathy detected by
repeated echocardiograms (twice per year). All three chil-
dren are treated with ACE inhibitors, b blockers, and
diuretics; no further deterioration of their cardiac function
was observed on repeated echocardiography during the last
5 years of follow-up.
Laboratory investigations
Most patients presented with chronic microcytic anemia
and recurrent episodes of leucopenia without thrombocy-
topenia. Transaminases were between 80 and 125 U/l
(controls \50 U/l) in most individuals (Table 2).
Clotting factor XI and antithrombin III activity were
decreased in all patients. Interestingly, no significant
bleeding event or thrombotic event was observed in any of
the patients.
Endocrine anomalies were mild, including decreased
cortisol levels without ACTH elevation and low IGF1
levels. Thyroid function was normal.
Genetic investigations
Mutation analysis in the DK1 gene revealed homozygous
mutations c.1222C [ G; (p.His408Asp) in all affected
surviving individuals in Family I and Family II. The
homozygous mutation c.912G[T (p.Trp304Cys) was
detected in all affected members of Family III.
The mutation c.1222C[G; p.His408Asp in the doli-
chol kinase gene in family I and family II segregated
with the disease: in patients 5 and patient 6 of family I
and in patients 2 and 3 of family II, the mutations were
detected in a homozygous form, and the parents from
both families were proven to be carriers. Homozygous
mutations c.912G[T; p.Trp304Cys were confirmed in the
affected patients 1, 3, and 4 in family III, whereas their
parents were proved to be carriers. The segregation was
further supported by showing a carrier state in patients 1
and 4 of family I and patient 1 of family II, correlating
with no clinical findings in these healthy family
members.
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The mutations were screened in a healthy control popu-
lation of same ethnicity and were absent in 50 healthy control
samples. The pathogenicity of the mutations was further
corroborated by the high conservation of the mutated amino
acids. Both the SIFT and PolyPhen programs predict these
changes to be damaging for protein function.
The mutations, which have been found in our patients,
are not reported in the Exome Variant Server database
[http://evs.gs.washington.edu/EVS/], suggesting that the
predicted heterozygosity in the European American and
African American population for these mutations is at
around 1:10,000.
Fig. 2 Electrocardiography of a DK1-CDG patient (II/3) with only mild dilation of his LV diameters (a) and of his older brother (II/2) just
before heart transplantation (b)
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Metabolic studies/transferrin isoelectric focusing
The transferrin isoelectric focusing pattern showed a CDG
type 1 pattern in all investigated patients. The tetrasialo-
transferrin (Tf4) ratio was decreased with a significant
elevation of the disialotransferrin (Tf2) fraction and
increase in the asialotransferrin levels (Tf0). The Tf2
fraction was in the range of 27–38% in family I, in the
range of 25–36% in family II, and in the range of 30–38%
in family III (controls: 3.3–7.6%).
There was no significant difference between the trans-
ferrin pattern before and after transplantation in the
investigated individuals’ serum (Table 3).
Pathological examination
In Patient I/5, light microscopic evaluation of the affected
heart at the time of the heart transplantation revealed
dilated cardiomyopathy with moderate interstitial fibrosis
and chronic epicarditis.
In Patient I/6, biopsy from the affected heart revealed
dilated cardiomyopathy with severe interstitial fibrosis.
In Patient II/2, biopsy from the affected heart revealed
biventricular dilated cardiomyopathy with interstitial
fibrosis.
In Patient III/2, pathological examination of the affected
heart revealed biventricular dilated cardiomyopathy with
myocytes fibrosis, severe interstitial fibrosis, chronic epi-
carditis, and a small endocardial thrombus.
Discussion
DK1-CDG, also known as dolichol kinase deficiency, is
caused by mutations in the DK1 (also labeled as TMEM15
or DOLK) gene (MIM 610746) [2], which encodes the
enzyme responsible for the final step of the de novo bio-
synthesis of dolichol phosphate. A defect in humans was
first described by Kranz et al. [17]. Dolichol phosphate is a
lipid carrier embedded in the endoplasmic reticulum
(ER) membrane essential for the synthesis of N-glycans,
GPI-anchors, and protein C- and O-mannosylation. The
availability of dolichol phosphate on the cytosolic side of
the ER is rate-limiting for N-glycosylation, and a defect in
its synthesis as in DK1-CDG leads to abnormal N-linked
glycosylation [1, 17].
A disruption of the dolichol metabolism leads to a broad
spectrum of anomalies. Cantagrel et al. [3] recently
described a new CDG form in seven families caused by a
defect in polyprenol reductase and affecting dolichol
metabolism. In these patients, several different tissues and
organs are affected due to SRD5A3 mutations, such as the
cerebellum, diverse ocular structures, or the skin [9].
Cardiac abnormalities were not detected, which was sur-
prising in view of the cardiac involvement found in the
corresponding SRD5A3 mutant animal model [3].
Dolichol is also required for the synthesis of O-mannose-
linked glycans, C-mannosylation, and glycophospholipid
anchor synthesis. Cardiomyopathy has been detected in
O-mannosylation defects [23] and combined N-and
O-linked glycosylation defects (DPM3-CDG) [19], giving
additional confirmation regarding the interplay of different
glycosylation steps and the abnormal glycosylation of
diverse proteins in heart, as a consequence. Furthermore,
little is known about the glycosylation-independent func-
tions of dolichol, which is a general membrane component
in mammalian cells [24, 25].
Very little is known about the clinical outcome of
patients with dolichol kinase deficiency. So far, the two
families with a lethal form of dolichol kinase deficiency
(CDG-Im) described by Kranz et al. [17] are the only
patients described in literature. The children died in
the first year of life from a severe infection or due to car-
diac failure and dilated cardiomyopathy. The neonatally
observed neurological involvement and severe muscular
hypotonia dominated the clinical presentation. All patients
had significant skin findings (hyperkeratosis, ichthyosis,
minimal hair growth), and one child had symptoms of
hypoglycemia, failure to thrive, and liver involvement.
In the present study, except for laboratory abnormalities,
and transient organ involvement during acute infection
episodes, no multi-organ involvement was detected. The
symptoms of progressive dilated cardiomyopathy were the
most prominent in the clinical picture. The skin findings
Table 3 Transferrin isoforms
before and after transplantation
in patients (abnormal levels in
bold)
Tf4: tetrasialo transferrin,
Tf3: trisialotransferrin,
Tf2: disialotransferrin,
Tf1: monosialotransferrin,
Tf0: asialotransferrin
Patient I/6 Patient II/2 Control
range
Before
transplantation
After
transplantation
Before
transplantation
After
transplantation
Tf0 10 22 8 9 0–3.2
Tf1 2 0 1 2 0–5
Tf2 29 38 32 25 3.3–7.6
Tf3 8 7 9 10 4.9–10.6
Tf4 34 24 31 28 47.3–62.7
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were only sporadic and not so severe. None of the patients
had significant dysmorphic features; ophthalmological and
neurological assessments were normal; hypoglycemia was
not observed; and failure to thrive during infancy was seen
in only two patients. Two of our patients presented with
signs and symptoms of fulminate heart failure and death, in
the beginning of their second decade of life. However, on
routine echocardiogram, all affected individuals with the
same TMEM15 (DK1) gene mutation showed to have mild
to moderate phenotype of dilated cardiomyopathy, already
in the first years of life.
The treatment strategies for children with asymptomatic
heart failure and cardiomyopathy are, in general, similar to
those recommended for adults with heart failure [26, 27].
They include ACE inhibitors and b blockers, in addition to
diuretics and even Digoxin. However, the efficacy of the
medical treatment in CDG-I patients is completely
unknown. Due to acute sudden death of 2 siblings from 2
unrelated families and rapid cardiac deterioration of 3 other
patients, a decision was taken to place all children with
DK1-CDG, even with mild dilated cardiomyopathy, on
ACE inhibitors, b blockers, and diuretics. Rhythm distur-
bances, e.g., frequent multifocal premature ventricular
beats and non-sustained ventricular tachycardia, might be
the first sign of cardiac ischemia due to the metabolic status
of the myocardium and should be aggressively treated.
Iijima et al. [5] had speculated that the decrease in major
coagulation inhibitors, particularly due to impaired glyco-
sylation of AT III, underlies the stoke-like episodes during
catabolic states (infection, fever) in CDG syndrome.
Arnoux et al. [28] reported on acute vascular events
(bleeding and thrombosis) and stroke-like events in
patients with CDG-Ia. Thromboses were either venous or
arterial. Acute vascular events occurred in patients younger
than 15 years, especially with fever and prolonged immo-
bilization. The paradoxical results—abnormal VIII and IX
factors in patients without vascular events and normal
results in patients with vascular events, while factor XI,
antithrombin, protein C, ASAT, and ALAT are abnormal in
both groups—could suggest a disequilibrium between
prothrombotic and antithrombotic factors in the at-risk
group. Vascular events may also occur in patients where
glycoproteins are proportionally more hypoglycosylated,
particularly protein C. Furthermore, acute fluid loss might
potentiate hypercoagulation. Recently, Footitt et al. [13]
reported on an 11-year-old girl with a background of
learning difficulties and severe dilated cardiomyopathy.
Prior to the diagnosis of CDG, her condition deteriorated;
she required mechanical support (Excor Berlin Heart) and
was listed for cardiac transplant. Despite aggressive ther-
apy, there were persistent difficulties achieving adequate
anticoagulation and she developed multiple life-threatening
thrombotic complications. In the present study, laboratory
hemostatic tests were abnormal in all our DK1-CDG
patients. However, none of the patients presented with
major bleeding, thrombosis, and stoke-like episodes. Three
of our patients were treated successfully with heart trans-
plantation. One needed ECMO while waiting for trans-
plantation. No pre- or postoperative and post-heart
catheterization bleeding have been reported in this sub-
group. Prophylactic administration of Aspirin and antico-
agulants for the prevention of thrombosis in children with
dilated cardiomyopathy remains unclear. Bleeding and
thromboses have been reported even in the same patient in
other subtypes of CDG like in CDG-Ia [28]. Since no acute
vascular and transient ischemic ‘‘stroke like’’ were reported
in our DK1-CDG patients, prophylaxis with low doses of
aspirin can be proposed after a first arterial thrombosis. The
families are advised to avoid prolonged immobilization,
dehydration, and infection.
We describe a wide spectrum of cardiac involvement in
patients with a disorder affecting dolichol synthesis. In
contrast to the severe outcome with early death reported by
Kranz et al. [17], we experienced various clinical cardiac
outcome. In our 3 families, siblings did not show any
symptoms of cardiac failure in infancy and early childhood.
Cardiac evaluation took place only after the death of a first
child (family I and III). So discrete dilated cardiomyopathy
in early infancy and childhood cannot be ruled out.
This is the first comprehensive description of clinical,
histological, and laboratory findings in a series of
patients with dolichol kinase defect. DK1-CDG is a
disorder with dilated cardiomyopathy with ichthyosiform
skin abnormalities and hypotonia in some of the patients
with a highly variable outcome. We expand the clinical
phenotype with the observation of microcytic anemia and
report on the laboratory abnormalities of abnormal
coagulation and normal endocrine studies in dolichol
kinase defect.
There are several DK1-CDG patients in our cohort with
long-term survival. In the presence of severe coagulation
abnormalities and decreased antithrombic factors, the
patients had no significant bleeding episodes and three of
them underwent successful heart transplantation without
thrombotic events. Given the high variability of the clinical
phenotype in DK1-CDG, it is important to realize that life-
threatening dilated cardiomyopathy can be the single
clinical manifestation of congenital disorders of glycosyl-
ation. Once the diagnosis of DK1-CDG is established,
repeated echocardiograms, at least twice per year, are
indicated. Treatment for heart failure should be well
thought of even in asymptomatic DK1-CDG patients with
discrete dilated cardiomyopathy. Our paper is the first
comprehensive study on the phenotype of DK1-CDG and
the first successful organ transplantation in CDG
syndrome.
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